At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 369 enrolled
Drug / intervention
GSK523338drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 16 Week Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of a New Medication (GSK523338) to Lower LDL-c and HbA1c in Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating GSK523338 for Diabetes Mellitus, Type 2. Completed, enrolled 369 participants across 85 sites in 6 countries.
Detailed Summary
This study evaluates the effect of medicines for type 2 diabetes and lipids control. This study will require about 6 office visits for lab tests and examinations. All study related medicines and medical examinations will be provided at no cost to the subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesAustralia, Canada, Mexico, Philippines, Puerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2005
First PostedNov 2005
Primary CompletionOct 2006
TodayJul 2026
First PostedNov 22, 2005
Enrollment StartAug 18, 2005
Primary CompletionOct 31, 2006
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 20.6 years ago
Interventions
GSK523338drug